KLRK1 and acute myeloid leukemia: In a first-in-human clinical trial in patients with acute myeloid leukemia (AML), NKG2D ligand-redirected CAR T cells had limited efficacy, which was attributed to insufficient levels of ligand expression on the surface of leukemic blasts of the patients [62].